• There are no suggestions because the search field is empty.

How to define your Clinical Performance Strategy?

Calander_icon
person-image
Kirsten Van Garsse, Director AR Services and Manager IVD - RA and Annelies Rotthier, Scientific Affairs and IVD Clinical Evidence Manager
Defining a clinical performance strategy for an in vitro diagnostic (IVD) device requires a structured approach. A solid strategy helps you stay focused and make realistic estimates around timelines and budgets. Discover the key components you’ll want to consider when defining your strategy.
 
How to define your Clinical Performance Strategy | QbD Group
4:29

 

1. Start with a clear intended purpose

 

A strong clinical performance strategy begins with a well-defined Intended Purpose. This statement lays the foundation for your approach, determining study design, applicable performance characteristics, and regulatory process. Several aspects of the intended purpose directly impact clinical performance strategy:
  • Function: The function of the assay will determine the clinical performance characteristics you need to evaluate and the regulatory requirements you’ll need to meet. It will also define the study population that needs to be evaluated.
  • Qualitative vs. Quantitative: Whether the assay provides qualitative results or quantitative measurements will affect the performance characteristics that apply to the assay and study setup as well as performance requirements.
  • Specimen Type: The type of specimen plays a critical role. For example, if the sample involves “surgically invasive sample-taking for the purpose of the performance study,” Annex XIV requirements apply.
  • Intended User: Devices for self-testing or near-patient testing require performance and usability testing in relevant environments. Summative usability studies are typically conducted during the validation phase, and efficiencies can be achieved by aligning these with the clinical performance study.

A clear and detailed intended purpose statement ensures that your clinical performance strategy is aligned with how the device will be used in real-world clinical settings.

Clinical performance may not be required for certain devices. For example, clinical performance data may not be expected for some class A devices.  In such cases a due justification must be given.

 

2. Know the State of the Art

 

Understanding the State of the Art is essential to define the clinical performance criteria that should be reached. This step ensures that your device meets current standards and expectations by:

  • Applicable guidance documents and regulations: Identify relevant regulations, standards or guidance documents, such as common specifications, that apply to your device.
  • Researching similar devices: Reviewing similar devices already on the market provides insight into the performance and features of similar products. This serves as input to define acceptance criteria for the clinical performance of your device.
  • Identifying reference methods or materials: Determining whether certified reference materials or methods exist for your device is essential for defining the strategy of your clinical performance, especially for quantitative methods.


By understanding the state of the art, you can ensure that your device meets the current standards and is competitive within the market.

 

 3. Define Performance Characteristics
 

Once you’ve established the intended purpose and understood the state of the art, you can define the appropriate clinical performance characteristics for your device, such as Diagnostic sensitivity and specificity, positive and negative predictive values, expected values in normal versus affected populations, …

It is equally important to establish acceptance criteria for each characteristic, ensuring they align with the state of the art and regulatory expectations.

 
 

4. Assess Available Clinical Performance Data

 

For devices already on the market, in Europe or in other jurisdictions, clinical performance data may already be available. This data can come from previous performance evaluation studies, scientific peer-reviewed literature or routine diagnostic use.

If sufficient data exists to support your device’s claims and performance characteristics, additional studies may not be necessary. However, it’s important to critically evaluate the data to ensure it aligns with your intended purpose and performance criteria.

In some cases, clinical performance can be demonstrated in an indirect way based on published data obtained with a reference device which is considered an established and standardized device. 

For new or novel devices, you will likely need to conduct performance studies to validate the device’s claims and meet regulatory requirements.

By addressing each of these elements systematically, you can develop an effective clinical performance strategy. This approach will not only ensure your IVD device meets regulatory standards but also positions it for success in the market.

 

 

 

Stay ahead in life sciences

Keeping up with the fast-paced life sciences industry doesn’t have to be overwhelming.

Our newsletter delivers the latest insights, industry updates, and expert content directly to your inbox, helping you stay informed and make smarter decisions.

Circles-banner-short

Discover more expert content

preview_image
Case study

Fast-Tracked Site Qualification for Clinical Trial Submission

QbD Group helped a biotech company complete 5 site qualification visits in just 3 weeks enabling a timely and compliant clinical trial submission.
preview_image
Webinar

Evidence Throughout the Lifecycle: Integrating Clinical Needs into Design & Documentation

Discover how to integrate clinical needs into medical device software design to meet MDR requirements. Watch our webinar on demand.
preview_image
Whitepaper

Clinical Evaluation for Medical Devices under MDR

This whitepaper will guide you through crucial regulatory documents pertaining to the clinical evaluation process of your medical device. Download now!
preview_image
Whitepaper

IVDR extension: what does this mean for you?

In this whitepaper, you will learn the impact of the IVDR transition extension and receive tips and strategies to navigate these regulatory changes.
preview_image
Whitepaper

State-of-the-art literature review: kick off the Clinical Evaluation of your Medical Device

This whitepaper will walk you through the steps of conducting solid systematic SOTA literature searches for your clinical evaluation. Download now.
preview_image
Whitepaper

Clinical investigations under MDR: key insights and practical experiences

This whitepaper covers clinical investigation authorization under MDR, the EU Legal Representative's role, and the MDR's impact on study conduct and post-market surveillance.
preview_image
Whitepaper

The pathway from idea to patient under MDR

This guide explains the pathway and steps needed to test your device in human subjects, aiming to get your product to market. Download now.
preview_image
Case study

CE Mark Renewal for bioXtra Products: A Success Story

Discover how Lifestream Pharma successfully renewed the CE mark for their BioXtra Dry Mouth products under the EU MDR. Learn about the challenges faced, the approach taken for compliance, and the results achieved.
preview_image
Webinar

Getting Started: Overcoming Initial Obstacles in Medical Device Software Development

Watch our webinar on demand and learn about regulatory obstacles, MDR, AI Act, and best practices for medical device software development and market entry.
preview_image
Webinar

Mastering Clinical Performance Studies under IVDR

In the evolving regulatory landscape of IVDs, demonstrating clinical performance is more crucial and challenging than ever. Discover more in this webinar on demand.
preview_image
Whitepaper

Clinical evidence for In Vitro Diagnostics under IVDR

In this whitepaper, we will guide you through the documents required for the demonstration of clinical evidence under the IVDR. Download now.
preview_image
Case study

Ensuring a smooth MDR transition for Oystershell's medical devices

The landscape of medical device regulations is constantly evolving, making it a challenge for companies to keep up. Our collaboration with Oystershell, which began in July 2023, highlights our expertise in transforming complex challenges into success stories, all with a touch of QbD Clinical magic.
preview_image
Case study

Successful clinical evaluation supports rapid CE marking of Minze Health's Uroflowmeter

QbD Clinical assisted Minze Health, a urology-focused medical devices company, in obtaining CE marking under MDR through clinical evaluation.